SUPPLEMENT SCIENCEInsights
Search

Search Insights

Try choline, nano-curcumin or probiotics.

    Ingredient guide · Ingredient reference

    Astaxanthin and lipids: dose-specific findings in a small trial

    A four-arm study reported selected triglyceride and HDL changes. LDL cholesterol and BMI did not change.

    Read the evidence ↓

    Supplement Science Insights Editorial Team

    Published September 23, 2026

    The study and its comparison

    Sixty-one non-obese adults with mildly elevated triglycerides and without diabetes or hypertension were randomized to placebo or 6, 12 or 18 mg astaxanthin daily for twelve weeks. [1]

    Reported multiple comparisons favored triglycerides at 12 and 18 mg and HDL at 6 and 12 mg. LDL and BMI were unchanged. Adiponectin changes correlated with HDL changes. [1]

    What the finding establishes

    A correlation does not establish the mechanism, and not every dose improved every endpoint. These are lipid measurements, not cardiovascular events. Funding and conflicts were not established from the abstract. The trial does not demonstrate a substitute for indicated lipid treatment. [1]

    A hypothetical distinction

    Imagine the middle dose improves two measures. This does not prove that progressively higher doses work better.

    Interpretation checklist — Astaxanthin and lipids
    DetailInterpretation
    Measured outcomeKeep the endpoint specific
    Study preparationNot every retail product
    Remaining uncertaintyNot resolved by a mechanism
    Astaxanthin and lipids: dose-specific findings in a small trial — original article outline diagram
    Original editorial diagram of this article’s sections; no product photograph or clinical finding is depicted.

    Sources for this article

    1. Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia.
      Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.